Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.

ESC heart failure·2026
Same author

Event rates in major Phase 3 heart failure trials over the last 20 years.

ESC heart failure·2026
Same author

Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Retrosternal extravascular implantable cardioverter-defibrillators: a systematic review of implant characteristics, defibrillation testing, and acute safety.

Future cardiology·2026
Same author

Successful coronary sinus reducer implantation in a patient with a pre-existing left ventricular pacing lead: a case report.

European heart journal. Case reports·2026
Same author

The Yentl Syndrome Revisited: Under-Diagnosis and Under-Treatment in Women with Wild-Type Amyloid Transthyretin Cardiomyopathy.

European heart journal. Quality of care & clinical outcomes·2026
Same journal

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026
Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026
Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026
Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026
Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026
Same journal

Advances in small extracellular vesicle analysis.

Advances in clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Biomarkers in heart failure.

Manuel Garofalo1, Giorgia Panichella1, Alberto Aimo2

  • 1Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.

Advances in Clinical Chemistry
|June 23, 2026
PubMed
Summary
This summary is machine-generated.

Biomarkers are crucial for managing heart failure (HF), aiding diagnosis and prognosis. Novel biomarkers and AI integration promise personalized HF care, moving beyond traditional approaches for better patient outcomes.

Keywords:
Atrial natriuretic peptidesBiomarkersCardiac troponinsGalectin-3Growth differentiation factor-15Heart failureHigh-sensitivity c-reactive proteinLong non-coding rnasMicroRNAsSoluble suppression of tumorigenicity-2

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jun 25, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Area of Science:

  • Cardiology and Clinical Biomarker Research
  • Translational Medicine and Precision Health

Background:

  • Heart failure (HF) is a major global health burden with complex pathophysiology.
  • Circulating biomarkers are vital for HF diagnosis, prognosis, and treatment guidance.
  • Established biomarkers like BNP/NT-proBNP have limitations, necessitating research into novel markers.

Purpose of the Study:

  • To review the evolving role of circulating biomarkers in heart failure management.
  • To highlight established and emerging biomarkers and their pathophysiological relevance.
  • To discuss the future potential of multimarker strategies and AI in personalized HF care.

Main Methods:

  • Review of current literature on established and novel biomarkers in HF.
  • Analysis of biomarker utility in diagnosis, prognostication, and therapeutic guidance.
  • Exploration of emerging technologies like omics and AI for biomarker integration.

Main Results:

  • BNP/NT-proBNP are cornerstones but influenced by clinical factors.
  • Cardiac troponins and hsCRP offer prognostic insights into myocardial injury and inflammation.
  • Novel biomarkers (Gal-3, sST2, GDF-15, MPO, MR-proADM) and non-coding RNAs provide incremental value.
  • Multimarker strategies and AI show promise for refined risk stratification.

Conclusions:

  • Biomarkers are essential pillars in modern heart failure care.
  • Emerging biomarkers and advanced technologies are transforming HF management.
  • The future of HF care lies in personalized, biomarker-guided strategies.